newsfilter
← Latest News
GlobeNewswire·

Grace Therapeutics Announces First Quarter 2026 Financial Results, Provides Business Update

Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) NDA Supported